COVID antibodies from infection typically peak around four months after symptoms begin and then decline steadily, with the most protective types remaining detectable for at least a year, though at reduced levels. Vaccine-induced antibodies follow a broadly similar arc but with a faster initial decay, and boosters or hybrid immunity (vaccination plus infection) meaningfully extend their durability. The picture is more nuanced than a single expiration date, because “antibody levels” and “immune protection” are not the same thing.
After Infection, Antibodies Peak Around Four Months
When your body fights off a SARS-CoV-2 infection, it ramps up production of several types of antibodies. The ones researchers care most about are IgG antibodies targeting the spike protein’s receptor-binding domain (RBD), because those closely track the ability to neutralize the virus. In a longitudinal study following COVID convalescents for over a year, anti-RBD IgG and neutralizing antibody levels climbed to a peak at roughly 120 days after symptom onset, then began a slow decline that leveled off after about 400 days.1Nature Microbiology. Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection By the time researchers measured them at the 16-month mark, the median person retained about 46% of their peak anti-RBD IgG level, and over 90% of convalescents had lost at least half their peak neutralizing titer.
In the earlier months, the trajectory looks reassuring. Anti-RBD IgG decayed slowly through the first 90 days, and only a tiny fraction of people lost detectable antibodies entirely during that window.2PubMed Central. Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients What matters here is not just whether antibodies are present but whether they can still block the virus. By 14 months, neutralizing capacity had dropped about sevenfold from its peak, and some individuals fell below the threshold of detection for neutralization, even though they still had measurable binding antibodies in standard blood tests.3PubMed Central. Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection In other words, an antibody test might still come back positive long after the antibodies have lost most of their punch against live virus.
Vaccine-Induced Antibodies Decay Faster Initially
After two mRNA vaccine doses, anti-spike IgG levels start high and then fall with a half-life of roughly 60 days.4npj Viruses. Estimating the decay of protective antibodies induced by SARS-CoV-2 mRNA vaccination and hybrid immunity That means about every two months, your circulating antibody level drops by half. A third (booster) dose pushes the peak about three times higher and extends the half-life to roughly 100 days, so the antibodies last meaningfully longer.4npj Viruses. Estimating the decay of protective antibodies induced by SARS-CoV-2 mRNA vaccination and hybrid immunity Separate research found a similar pattern: a booster extended anti-spike half-life from about 63 days to 115 days, an increase of roughly 70–84%.5Scientific Reports. SARS-CoV-2 booster vaccine dose significantly extends humoral immune response half-life beyond the primary series
Neutralizing antibodies follow a similar arc but with half-lives ranging between 29 and 60 days depending on the group studied. People who had been both infected and vaccinated, or who received boosters, tended to decay more slowly than those with vaccination alone.6PubMed Central. Recurrent waning of anti-SARS-CoV-2 neutralizing antibodies despite multiple antigen encounters One practical detail: among people who had not been infected, the waning rate slowed by about 17% per month after a third dose compared to two doses alone.7PubMed Central. Durability and determinants of anti-SARS-CoV-2 spike antibodies following the second and third doses of mRNA COVID-19 vaccine
Hybrid Immunity Lasts Longer and Works More Broadly
If you have been both vaccinated and infected, you have what researchers call hybrid immunity, and it consistently outperforms either exposure alone. A study of people who received an adenovirus-based vaccine and then had a breakthrough infection found that binding antibodies stayed at protective levels for at least 360 days, and the antibodies could neutralize multiple variants including Beta, Gamma, Delta, and (to a lesser extent) Omicron.8PubMed Central. Longevity of hybrid immunity against SARS-CoV-2 in adults vaccinated with an adenovirus-based COVID-19 vaccine Reinfections during the follow-up period actually boosted antibody levels further, and none led to severe disease.
This cross-neutralizing breadth is one reason hybrid immunity is considered the most robust form of COVID protection. It is not just that the antibody numbers stay higher for longer; the immune system has seen the virus from multiple angles and generated a wider range of antibodies, making it harder for variants to slip through.
Why Protection Outlasts the Antibodies You Can Measure
Circulating antibody levels are the easiest thing to measure, so they get the most attention. But they are only one layer of immune defense. Behind those declining numbers sits a deeper reservoir of immune memory that can reactivate when needed.
Memory B cells, the cells that remember how to make antibodies, actually increase or hold steady even as circulating antibody levels drop after infection. More strikingly, these B cells keep improving. Analysis of over 1,200 monoclonal antibodies from recovered patients showed that memory B cells progressively accumulated mutations that made them better at binding and neutralizing the virus, a process called affinity maturation.9PubMed Central. Prolonged evolution of the human B cell response to SARS-CoV-2 infection A separate study tracking individual B cell lineages over six months confirmed that antibodies produced later were not only more mutated but maintained or increased their neutralizing ability.10Cell. Longitudinal Evolution of the Human B Cell Response after Severe COVID-19 This is your immune system quietly upgrading its weapons even after the infection is gone.
Beyond B cells, the bone marrow itself becomes a long-term antibody factory. Researchers who examined bone marrow samples from vaccinated individuals found SARS-CoV-2 spike-specific plasma cells in every sample tested, and about one-fifth of these cells had the hallmarks of long-lived “memory plasma cells” capable of producing antibodies for years.11PubMed Central. SARS-CoV-2 specific plasma cells acquire long-lived phenotypes in human bone marrow This finding helps explain why antibodies show a two-phase decay: a fast initial drop as short-lived plasma cells die off, then a much slower decline sustained by these bone-marrow residents, with an estimated extended half-life over 200 days.12PubMed Central. Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells
T Cells Stick Around Even When Antibodies Fade
T cells do not prevent infection the way antibodies do, but they are critical for clearing infected cells and preventing severe disease. Virus-specific CD4+ and CD8+ T cells generated after SARS-CoV-2 infection are long-lived, with estimated half-lives around 200 days.12PubMed Central. Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells A study that checked in at seven months found that while neutralizing antibodies had dropped significantly, the proportion of spike-specific CD4+ T cells had not budged.13PubMed Central. Decline in neutralising antibody responses, but sustained T-cell immunity, in COVID-19 patients at 7 months post-infection
This persistence of T cells is a big part of why people who have been infected or vaccinated remain well-protected against severe illness and hospitalization even months after their antibody levels have fallen below the level that would prevent a mild or asymptomatic infection. The immune system’s backup layers are slower to deploy but effective at keeping you out of the hospital.
What Antibody Levels Actually Mean for Protection
Researchers have tried to pin down the relationship between antibody numbers and real-world protection. One influential modeling study estimated that the neutralizing level needed for 50% protection against any detectable infection was about 20% of the average convalescent level, whereas 50% protection against severe disease required only about 3% of that same benchmark.14Nature Medicine. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection In practical terms, this means you can lose the large majority of your antibodies and still retain strong protection against serious outcomes.
A large real-world study confirmed this gradient. People with even low-but-detectable antibody levels had a 42% lower risk of symptomatic infection compared to those with no detectable antibodies. Those with the highest antibody levels saw a 62% reduction in symptomatic infection and an 87% reduction in severe outcomes like hospitalization or death.15PubMed Central. SARS-CoV-2 SPIKE Antibody Levels can Indicate Immuno-Resilience to Re-infection The takeaway is that higher antibody levels correlate with better protection in a dose-dependent way, but even modest levels offer meaningful defense, especially against severe disease.
Variants Erode Antibody Effectiveness Faster Than Time Does
Antibody waning from the passage of time is one problem. A potentially bigger problem is that new variants can dodge existing antibodies regardless of how high the levels are. Research after the Omicron wave illustrated this starkly. Even after a booster dose, neutralizing titers against Omicron subvariants BA.2.75.2 and BQ.1.1 were 35- and 50-fold lower, respectively, than titers against the ancestral strain. Only about 55–65% of boosted participants had detectable neutralizing activity against these newer variants, and by six months that figure had dropped to near zero.16PubMed Central. Durability of immune responses to the booster mRNA vaccination against COVID-19
This is the dynamic that drives updated vaccine formulations. Time-based waning is gradual and partly offset by memory B cells and T cells. Variant escape, by contrast, can knock out a large fraction of your neutralizing capacity overnight, because the virus has changed the very part of itself your antibodies were trained to recognize. SARS-CoV-2 is not unique here; other respiratory viruses like influenza and common-cold coronaviruses use the same strategy of mutating the surface regions the immune system targets most heavily.17The Lancet Microbe. The durability of immunity against reinfection by SARS-CoV-2: a comparative evolutionary study
Repeated Boosters Hit a Ceiling
A natural question is whether you can just keep boosting to keep antibodies high. The answer involves a trade-off. Each additional booster slows the rate of decay: the time constant for antibody decline lengthened with each successive dose in one detailed case analysis.18PubMed Central. Exponential decline, ceiling effect, downregulation, and T-cell response in immunoglobulin G antibody levels after messenger RNA vaccine boosters But the peak antibody level hit a ceiling. After a fourth dose, peak IgG reached only about 60% of the post-third-dose peak. After a sixth dose, peak IgG was about 56% of the post-fifth-dose peak. The body appears to impose a kind of ceiling effect, where additional doses raise the floor (baseline levels between doses went up) but the peak gets progressively clipped.
This does not mean boosters stop working. Even modest bumps in antibody levels translate to real protection, particularly against severe disease. But it does suggest diminishing returns from repeatedly giving the same antigen, which is part of the rationale for updating vaccine formulations rather than simply adding more identical doses.
Who Loses Antibodies Faster
Not everyone’s immune response declines at the same rate. Age is a consistent factor. Older adults tend to produce lower peak antibody levels after vaccination and start from a lower baseline, though interestingly, the rate of waning after boosters does not appear to differ much by age.19PubMed. COVID-19 vaccination-induced antibody responses and waning by age and comorbidity status in a large population-based prospective cohort study The problem for older adults is mainly the initial response being weaker, which means they start their decline from a lower point and cross protective thresholds sooner.20PubMed Central. Waning effectiveness of SARS-CoV-2 mRNA vaccines in older adults: a rapid review
People with compromised immune systems face a steeper challenge. Immunocompromised individuals consistently show reduced durability across all adaptive immune responses, not just for SARS-CoV-2 but for other respiratory viruses as well.21PubMed Central. Durability of Adaptive Immunity in Immunocompetent and Immunocompromised Patients Across Different Respiratory Viruses: RSV, Influenza, and SARS-CoV-2 Among cancer patients specifically, people with blood cancers had the shortest estimated duration of neutralizing antibodies, around 113–127 days against certain variants, compared to about 146–226 days for those with solid tumors, with the specific vaccine platform also making a difference.22PubMed Central. Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients
Children’s Antibodies Last Remarkably Longer
One of the more surprising findings in the durability literature involves very young children. After natural infection, infants and young children showed anti-spike IgG with an estimated half-life of roughly 800 days, compared to about 187 days in adults in the same study.23iScience. Humoral immune responses to SARS-CoV-2 in infants and young children Put simply, a young child’s antibodies declined so slowly that the mathematical model could not confidently distinguish the decay from zero. The reasons are not fully understood but likely relate to the vigor of the developing immune system and the way first exposures tend to imprint more durably than later ones.
Mucosal Antibodies in the Nose and Throat
Most research on COVID antibody durability measures antibodies in blood, but the virus enters through the nose and throat, where a separate layer of mucosal immunity operates. After primary infection, mucosal antibodies against spike and RBD were detectable and remained elevated at nine months, although some waning occurred between one and nine months.24Nature Communications. SARS-CoV-2 mucosal antibody development and persistence and their relation to viral load and COVID-19 symptoms The anti-nucleocapsid mucosal response was more restricted, mainly limited to IgG.
This matters because current injectable vaccines are good at generating systemic (blood) antibodies but less effective at producing mucosal immunity. Natural infection does both. The gap in mucosal immunity after vaccination alone may partly explain why vaccinated people can still get infected in the upper respiratory tract even when they are well-protected against severe disease. Nasal vaccine formulations being developed by several research groups aim to close this gap.
Antibody Levels Can Mislead Without Context
If you have gotten an antibody test and are trying to interpret the number, a few things are worth knowing. Different commercial tests measure different antibodies (anti-spike vs. anti-nucleocapsid, total antibodies vs. IgG only), and their sensitivity varies substantially, from about 69% to 95%, depending on the assay and when the sample is taken. Spike or RBD-targeting IgG tests perform best when blood is drawn more than two months after infection, while total antibody tests are more reliable in the first 30 days.25PubMed Central. The Performances of Three Commercially Available Assays for the Detection of SARS-CoV-2 Antibodies at Different Time Points Following SARS-CoV-2 Infection
There is also a disconnect between what standard binding antibody tests show and what neutralization assays reveal. In one study of vaccinated individuals, anti-RBD IgG levels dropped sharply over six months, yet neutralizing bioactivity remained high in almost everyone.26Clinica Chimica Acta. Long-term decay of anti-RBD IgG titers after BNT162b2 vaccination is not mirrored by loss of neutralizing bioactivity against SARS-CoV-2 The antibodies that remained were fewer in number but had been refined to be better at their job. So a declining number on your test report does not necessarily mean your protection has fallen by the same proportion.
Prior Common-Cold Coronavirus Exposure and Cross-Reactivity
Your immune history with other coronaviruses can influence how you respond to SARS-CoV-2, and not always in the direction you might hope. People with higher pre-existing antibodies against OC43, a common-cold betacoronavirus, tended to mount a bigger SARS-CoV-2 IgG response after infection, which sounds beneficial until you consider the catch: higher SARS-CoV-2 IgG and IgM levels also correlated with more severe disease. An early boost in common-cold coronavirus antibodies during the first two weeks of a SARS-CoV-2 infection was associated with worse outcomes.27Cell Host & Microbe. Pre-existing humoral immunity to human common cold coronaviruses negatively impacts the protective SARS-CoV-2 antibody response The immune system may be recalling old, partially relevant antibodies instead of generating the precise new ones needed, a phenomenon sometimes called “original antigenic sin.” The relationship between prior coronavirus exposure and COVID outcomes remains an active area of research, and the effects are not straightforward.